Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited)

v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Stock [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 2,774 $ 8,771 $ 194,133,511 $ (176,902,086) $ 253,734 $ (5,281,180) $ 12,215,524
Beginning balance, shares at Dec. 31, 2020 2,774,394 8,772,198          
Issuance of common stock and warrants, net of issuance costs $ 950 11,449,916 11,450,866
Issuance of common stock and warrants, net of issuance costs, shares   950,000          
Exercise of pre-funded warrants $ 3,679 3,679
Exercise of pre-funded warrants, shares   3,679,630          
Share-based expense 297,337 297,337
Exercise of purchase warrants $ 4 (4)
Exercise of purchase warrants, shares   4,032          
Issuance of common stock to vendor $ 7 (7)
Issuance of common stock to vendor, shares   7,153          
Net loss (3,803,499) (3,803,499)
Ending balance, value at Sep. 30, 2021 $ 2,774 $ 13,411 205,880,753 (180,705,585) 253,734 (5,281,180) 20,163,907
Ending balance, shares at Sep. 30, 2021 2,774,394 13,413,013          
Beginning balance, value at Jun. 30, 2021 $ 2,774 $ 8,772 194,319,716 (179,354,709) 253,734 (5,281,180) 9,949,107
Beginning balance, shares at Jun. 30, 2021 2,774,394 8,773,683          
Issuance of common stock and warrants, net of issuance costs $ 950 11,449,916 11,450,866
Issuance of common stock and warrants, net of issuance costs, shares   950,000          
Exercise of pre-funded warrants $ 3,679 3,679
Exercise of pre-funded warrants, shares   3,679,630          
Share-based expense 111,131 111,131
Exercise of purchase warrants $ 3 (3)
Exercise of purchase warrants, shares   2,547          
Issuance of common stock to vendor $ 7 (7)
Issuance of common stock to vendor, shares   7,153          
Net loss (1,350,876) (1,350,876)
Ending balance, value at Sep. 30, 2021 $ 2,774 $ 13,411 205,880,753 (180,705,585) 253,734 (5,281,180) 20,163,907
Ending balance, shares at Sep. 30, 2021 2,774,394 13,413,013          
Beginning balance, value at Dec. 31, 2021 $ 2,774 $ 13,465 205,952,729 (182,547,265) 253,734 (5,281,180) 18,394,257
Beginning balance, shares at Dec. 31, 2021 2,774,394 13,466,603          
Issuance of common stock in connection with purchase of in-process research and development $ 875 804,125 805,000
Issuance of common stock in connection with purchase of in-process research and development, shares   875,000          
Share-based expense 392,829 392,829
Exercise of purchase warrants $ 2 (2)
Exercise of purchase warrants, shares   1,984          
Net loss (5,069,818) (5,069,818)
Ending balance, value at Sep. 30, 2022 $ 2,774 $ 14,342 207,149,681 (187,617,083) 253,734 (5,281,180) 14,522,268
Ending balance, shares at Sep. 30, 2022 2,774,394 14,343,587          
Beginning balance, value at Jun. 30, 2022 $ 2,774 $ 14,342 207,012,317 (186,813,066) 253,734 (5,281,180) 15,188,921
Beginning balance, shares at Jun. 30, 2022 2,774,394 14,343,587          
Share-based expense 137,364 137,364
Net loss (804,017) (804,017)
Ending balance, value at Sep. 30, 2022 $ 2,774 $ 14,342 $ 207,149,681 $ (187,617,083) $ 253,734 $ (5,281,180) $ 14,522,268
Ending balance, shares at Sep. 30, 2022 2,774,394 14,343,587